Omalizumab Drug Survival Reaches 3.1 Years in Chronic Urticaria
A JAMA Dermatology meta-analysis of 4,516 patients found median omalizumab drug survival of 3.1 years in chronic urticaria, with discontinuation driven more by disease control than adverse events.